小木槌
发表于 2025-3-28 17:02:33
Bernard-Soulier Syndromemore specific laboratory studies such as aggregometry assays, flow cytometry, and molecular analysis can help to precise and timely diagnosis of disorder. BSS treatment includes supportive cares as well as specific treatment of bleeding episodes.
neutral-posture
发表于 2025-3-28 19:17:38
http://reply.papertrans.cn/24/2355/235476/235476_42.png
Sad570
发表于 2025-3-29 01:34:13
http://reply.papertrans.cn/24/2355/235476/235476_43.png
Mucosa
发表于 2025-3-29 04:24:55
Hemophilia Bcurring in ~1% of patients remains as a challenge of replacement therapy that can cause infused FIX concentrate to be less efficient. Gene therapy is the only definitive curative option, but some time will pass before it becomes available as a routine treatment choice.
泥土谦卑
发表于 2025-3-29 07:42:31
Book 20181st editionces for disease-related morbidity and mortality. The authors are acknowledged specialists in the field from across the world who have particular expertise in the disorder that they discuss. The book will be of value to hematologists, oncologists, pediatricians, laboratory specialists and technicians, general physicians, and trainees. .
Estimable
发表于 2025-3-29 11:28:45
enges that they pose.Provides up-to-date guidance on use of This book describes in detail the clinical presentation, diagnosis, and management of a wide range of congenital bleeding disorders. It will assist readers in overcoming the significant challenges involved in clinical and laboratory diagnos
BUOY
发表于 2025-3-29 18:31:24
Daniela Meneses Sala,Corina Rueda-Borrerothe more frequent cross-reactive material negative (CRM−) and the rare cross-reactive material positive (CRM+). Different therapeutic choices are available including fresh frozen plasma (FFP) and FXI concentrates that can provoke inhibitor formation, while recombinant FVII can be used for such patients.
含糊
发表于 2025-3-29 21:38:28
Book 20181st editionaders in overcoming the significant challenges involved in clinical and laboratory diagnosis and in providing effective clinical care that makes optimal use of new products, including recombinant factor. .concentrate. The coverage ranges from hemophilia A and B and von Willebrand disease to rare ble
两栖动物
发表于 2025-3-30 01:06:33
http://reply.papertrans.cn/24/2355/235476/235476_49.png
和蔼
发表于 2025-3-30 04:18:19
http://reply.papertrans.cn/24/2355/235476/235476_50.png